|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, April 08, 2012 ) New York, NY -- At the conclusion of each week, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. Although focusing intently on the biotech and healthcare sectors, due attention is also given to potential market-moving or game-changing companies in a broad variety of markets and industries. The 'Weekly Stock Watch' will also introduce new companies for coverage and identify some stocks that may have entered 'buy territory'.
The first trading week of the new quarter is in the books, and while the DOW stood firm above the 13,000 mark last week, a quick scan of the headlines shows us that sentiment has quickly turned towards expectations of a broad market downturn.
Additionally, attention is again on the European debt crisis, with Spain being labeled as the 'new Greece'. Any discouraging news from across the pond also doesn't serve well in the US markets.
The jobs report issued last Friday failed to inspire confidence in many media outlets, given that the number of jobs added in March fell short of expectations. Markets were closed on Friday, however, so any reaction by investors will be seen this week.
Eyes will also be on earnings this week, with powerhouses like Google (GOOG), JPMorgan Chase (JPM) and Wells Fargo (WFC) all set to release numbers, and any disappointments there would just add to any existing negative sentiment.
Consensus has it, though, that earnings for these big players will be in-line with expectations.
Ampio Pharmaceuticals (AMPE): Positive updates from all aspects of the Ampio Pharmaceuticals (AMPE) pipeline over the past few months ran shares towards the four dollar mark earlier this year, but had since retreated when news last week that the company was moving forward to seek an approval for Zertane in Australia drew harsh criticism from the author of a popular biotech blog.
The argument was that companies seeking approvals for products in overseas markets do so in order to boost share prices back in the US markets, since any product strong enough to garner an approval would be brought to market in the US first.
What wasn't mentioned on the subject, however, was that the company has stated many times previously that the idea to seek regional overseas partners for Zertane rather than concentrate on the US market is because the FDA does not recognize premature ejaculation (PE) as a medical need, therefore seeking approval in the US for PE is not an option.
Shares dropped a modest five percent on the negative opinion piece, although on light volume, an indication that investors paid little notice to the blogger.
Later this year it is expected that trials will commence for Ampio's two other primary pipeline products, Optina and Ampion, which will be geared towards the approval requirements of the US FDA.
AMPE has traded with extreme volatility over the past year, hitting as high as near ten dollars, with lows of under three.
While trading towards the lower end of that spectrum, it could be worth taking a look at this company as the pipeline story continues to play out.
Immunocellular Therapeutics (IMUC): A late volume spike on Thursday resulted in Immunocellular shares closing up three percent on the day, at just under the three dollar mark.
This company's share price has been on the run for the better part of 2012 thus far after having secured funding while attracting new institutional interest, acquired new technology to boost the pipeline, and prepared to move to a larger trading exchange, said to be the AMEX.
Immunocellular announced last week the completion of a technology transfer to a second manufacturing site that will allow for an increase in manufacturing and production of the company's immunotherapeutic cancer treatment ICT-107, currently being tested in Phase II trials for glioblastoma.
This has already proven to be a successful year for Immunocellular and continues to be a company to watch in the growing cancer immunotherapy sector.
Although Thursday's spike was carried by little volume, it'll be worth keeping an eye on this one during the coming trading week.
Coronado Biosciences (CNDO): Volume has picked up substantially for Coronado Biosciences (CNDO) over the past few months, and with it the share price has followed. As discussed last week, Coronado took a very low-profile approach to becoming a publicly-traded company, but since then shares have been gaining traction and momentum in the marketplace due to the growing awareness of the company's two distinct pipelines.
CNDO-109 is being developed as a biologic agent against multiple cancer types, starting with acute myeloid leukemia, and CNDO-201 has been highly successful thus far in trials using ova from the porcine whipworm as a treatment for Crohn's Disease. The successes of the Crohn's applications has led Coronado to advance plans to use CNDO-201 in other indications, as well, including Multiple Sclerosis and Ulcerative Colitis.
Coronado shares traded with some volatility last week, with about a $1.50 differential between the highs and lows, and more of that pattern could be expected as the pipeline story gets out and investors look to take up positions.
Interim Crohn's data is due this quarter, while another trial is also expected to be initiated within months. Both events could provide news and exposure catalysts for the company.
With volatility and volume increasing, CNDO will be one to keep an eye on this week. Shares were up by roughly three percent on Friday.
For complete version of this week's 'Weekly Stock Watch' visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-april-9-13-ampe-pbth-imuc-nby-nriff-cndo-siga-imsc-yhoo-fb-siri-cvm-aapl-sbux-mcd-agen
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFCÂ’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com 
Source: EmailWire.com
|
|
|
|
